Skip to main content

Table 1 Clinical and laboratory variables at baseline and follow-up

From: Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome

Clinical variables

Rosiglitazone therapy

Placebo therapy

Rosiglitazone therapy

Placebo therapy

 
 

Baseline

Follow-up

P-value

Baseline

Follow-up

P-value

Δ baseline-follow-up

Δ baseline-follow-up

P-value

Age (yrs)

60 ± 6

61 ± 6

< 0.001

57 ± 5

58 ± 5

< 0.001

   

Body mass index (kg/m2)

30.3 ± 4.5

28.7 ± 4.8

0.001

31.4 ± 4.9

29.2 ± 3.8

0.022

-1.6 ± 1.0

-2.2 ± 2.5

0.5

Waist circumference (cm)

112 ± 11

104 ± 14

0.001

111 ± 12

102 ± 10

0.005

-8 ± 5

- 8 ± 7

0.9

Systolic blood pressure (mmHg)

154 ± 23

136 ± 15

0.021

149 ± 14

135 ± 11

0.001

-18 ± 21

-14 ± 9

0.6

Diastolic blood pressure (mmHg)

91 ± 11

78 ± 8

0.001

89 ± 6

78 ± 5

< 0.001

-13 ± 9

-11 ± 5

0.6

Antihypertensive drugs, N (%)

2 (20)

4 (40)

0.5

4 (40)

4 (40)

1.0

   

Laboratory variables

         

Triglycerides (mmol/l)

1.8 ± 0.5

1.4 ± 0.3

0.008

1.9 ± 0.7

1.7 ± 0.6

0.3

-0.4 ± 0.4

-0.2 ± 0.5

0.3

HDL cholesterol (mmol/l)

1.2 ± 0.2

1.4 ± 0.2

0.002

1.2 ± 0.2

1.2 ± 0.1†

0.7

0.2 ± 0.2

0.02 ± 0.2

0.024

LDL cholesterol (mmol/l)

3.8 ± 0.8

4.3 ± 0.6

0.079

3.9 ± 0.4

3.8 ± 0.5

0.7

0.6 ± 0.9

-0.06 ± 0.4

0.063

Total cholesterol (mmol/l)

5.8 ± 0.9

6.3 ± 0.7

0.1

5.9 ± 0.6

5.8 ± 0.6

0.5

0.6 ± 1.0

-0.1 ± 0.6

0.075

Fasting blood glucose (mmol/l)

5.0 ± 0.6

4.8 ± 0.7

0.098

5.7 ± 1.0

5.3 ± 1.1

0.071

-0.3 ± 0.5

-0.4 ± 0.6

0.6

HbA1c (%)

5.2 ± 0.6

5.3 ± 0.4

0.3

5.2 ± 0.4

5.3 ± 0.3

1.0

0.1 ± 0.3

0.0 ± 0.4

0.5

Insulin (mmol/l)*

11.5 (11.3)

6.0 (4.3)

0.034

11.5 (9.3)

7.0 (5.8)

0.007

-4.2 ± 5.0

-7.6 ± 7.3

0.3

HOMA-IR (mmol/l × mU/l)*

1.5 (1.5)

0.6 (0.5)

0.021

1.6 (1.1)

0.9 (0.8)

0.007

-0.6 ± 0.6

-1.1 ± 1.0

0.2

hs-CRP (mmol/l)*

2.4 (3.1)

1.6 (1.7)

0.047

2.6 (0.9)

2.6 (2.6)

0.6

-1.7 ± 2.5

7.0 ± 21.2

0.2

  1. Data are expressed as mean ± SD. * Variables were non-normally distributed and therefore expressed as median (interquartile range); Mann-Whitney U test or Wilcoxon singed rank test were used for comparison between groups and between baseline and follow-up, respectively.
  2. † p < 0.05 between subjects who received Rosiglitazone or placebo therapy at follow-up.
  3. HbA1c: glycated hemoglobin, HDL cholesterol: high-density lipoprotein cholesterol, HOMA-IR: homeostasis model assessment of insulin resistance (fasting blood glucose (mmol/l) × fasting insulin (mU/l)/22.5), hs-CRP: high-sensitivity C-reactive protein, LDL cholesterol: low-density lipoprotein cholesterol.